Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review.

Treuer T, Méndez L, Montgomery W, Wu S.

Neuropsychiatr Dis Treat. 2016 May 3;12:1061-83. doi: 10.2147/NDT.S97724. eCollection 2016. Review.

2.

Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review.

Lv XZ, Shu Z, Zhang YW, Wu SS, Zhan SY.

Transl Pediatr. 2012 Jul;1(1):47-53. doi: 10.3978/j.issn.2224-4336.2012.04.04. Review.

3.

A critical appraisal of atomoxetine in the management of ADHD.

Childress AC.

Ther Clin Risk Manag. 2015 Dec 23;12:27-39. doi: 10.2147/TCRM.S59270. eCollection 2016. Review.

4.

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.

Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK.

J Child Adolesc Psychopharmacol. 2014 Oct;24(8):426-34. doi: 10.1089/cap.2014.0005. Epub 2014 Jul 14.

5.

Clinical Characteristics of Children and Adolescents with a Primary Tic Disorder.

Specht MW, Woods DW, Piacentini J, Scahill L, Wilhelm S, Peterson AL, Chang S, Kepley H, Deckersbach T, Flessner C, Buzzella BA, McGuire JF, Levi-Pearl S, Walkup JT.

J Dev Phys Disabil. 2011 Feb;23(1):15-31.

6.

Treatment of Tourette syndrome.

Kurlan RM.

Neurotherapeutics. 2014 Jan;11(1):161-5. doi: 10.1007/s13311-013-0215-4.

7.

Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.

Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK.

J Cent Nerv Syst Dis. 2012 Dec 20;5:1-17. doi: 10.4137/JCNSD.S6691. Print 2013.

8.
10.

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group.

Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96. doi: 10.1007/s00787-011-0163-7. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.

11.

European guidelines on managing adverse effects of medication for ADHD.

Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group.

Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3.

12.

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF.

J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-93. doi: 10.1097/CHI.0b013e3181b26e9f.

13.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.

Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D.

Neuropsychiatr Dis Treat. 2009;5:215-26. Epub 2009 Apr 8.

14.

Atomoxetine: a novel treatment for child and adult ADHD.

Ledbetter M.

Neuropsychiatr Dis Treat. 2006 Dec;2(4):455-66.

15.
16.

The management of tics.

Shprecher D, Kurlan R.

Mov Disord. 2009 Jan 15;24(1):15-24. doi: 10.1002/mds.22378. Review.

17.

Pediatric psychopharmacology update: psychostimulants and tics - past, present and future.

Pidsosny IC, Virani A.

J Can Acad Child Adolesc Psychiatry. 2006 May;15(2):84-6. No abstract available.

18.

Tourette syndrome and obsessive-compulsive disorder.

Lombroso PJ, Scahill L.

Brain Dev. 2008 Apr;30(4):231-7. Epub 2007 Oct 15. Review.

19.

Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement.

Gilbert DL, Zhang J, Lipps TD, Natarajan N, Brandyberry J, Wang Z, Sallee FR, Wassermann EM.

Clin Neurophysiol. 2007 Aug;118(8):1835-41. Epub 2007 Jun 27.

Items per page

Supplemental Content

Write to the Help Desk